OBJECTIVES: To compare rates of unscheduled clinician-patient encounters in patients who have undergone benign minimally invasive hysterectomy before and after the institution of the Enhanced Recovery After Surgery (ERAS) program. MATERIALS AND METHODS: A retrospective analysis evaluating women who underwent minimally invasive hysterectomy for benign indications was completed. We compared patients who underwent surgery the year prior to the implementation of an ERAS protocol (2012) with those who underwent surgery one year after ERAS was implemented (2014). The primary outcome was unscheduled clinician-patient encounters, which included patient-initiated phone calls, emergency room visits, and unscheduled post-operative office visits. Additional covariates measured include number of procedures performed in addition to the hysterectomy, operative time, readmission, estimated blood loss, and concomitant sling. RESULTS: A total of 90 women were included in the pre-ERAS group and 110 in the post-ERAS group. The two groups had no significant demographic differences. After implementation of ERAS, there was a significant increase in unscheduled patient encounters. The number of patients who initiated post-operative phone calls within two weeks of their surgery date increased from 39% (n¼35) before ERAS implementation to 68% (n¼75) after ERAS implementation (p¼<0.0001). Furthermore, additional medical care including any phone calls, inperson unscheduled post-operative visits or emergency room visits also significantly increased after ERAS implementation from 42% (n¼38) to 75% (n¼82) (p¼0.0001, OR 4.01). The odds of a patient seeking in-person medical care within two weeks post-operatively were three times higher if a concomitant sling procedure was performed regardless of ERAS protocol (p¼0.04, OR 3.16). There were no significant differences in readmission rates, operative time, blood loss, or emergency room visits between the two groups. CONCLUSION: ERAS protocol has been shown to be beneficial and safe in gynecologic surgery; however, when applied to benign hysterectomy, the gynecologist may need to anticipate an increase in the volume of unscheduled patient encounters. Managing this burden may require allocation of additional resources such as increased staff assistance or designated clinical time by the physician. Further research on ways to minimize unscheduled patient encounters after ERAS implementation should be evaluated. and Activity Assessment Scale (AAS) (0-100; higher score ¼ higher activity) prior to surgery and at 2 weeks, 4-6 weeks, and 3 months postoperatively. The SF-36 was completed at baseline, 6, 12, and 24 months after surgery; the Bodily Pain, Physical Functioning, and Role-Physical subscales were used for this analysis (higher scores ¼ less disability). Self-reported pain medication use was also collected. RESULTS: Before surgery, average pain at rest and during normal activity were (adjusted mean AE standard error) 2.2+0.2 and 2.8+0.3 (range 0-10 and 0-9, respectively); both increased slightly from baseline at 2 weeks (+0.7 for both, p<0.01 compared to pre-surgery) then decreased below baseline at 3 months (-0.9 and -1.1 respectively, p<.001), with no differences between surgical groups. Pain during exercise/strenuous activity and worst pain decreased below baseline levels at 4-6 weeks (-1.3, p¼.01 and -1.0, p¼.002) and 3 months (-2.0 and -1.5, p<.0001) without differences between surgical groups. Functional activity as measured by the AAS improved from baseline at 4-6 weeks (+9.2, p<.0001) and 3 months (+13.8, p<.0001). SF-36 Bodily Pain, Physical Functioning and Role-Physical Scales demonstrated significant improvements from baseline at 6, 12, and 24 months with no differences between groups (24 months: +5.6, +5.8 and +4.7 respectively, p<.0001 for each). Use of narcotic pain medications was reported by 14% of participants prior to surgery, 54% at 2 and 26% at 4-6 weeks post-operatively; thereafter, use was similar to baseline rates until 24 months when it decreased to 7%. Use of non-narcotic pain medication was reported by 48% of participants prior to surgery, 69% at 2 weeks and similar to baseline at 3 months; thereafter use dropped steadily to 27% at 2 years. CONCLUSION: Pain and functional activity improve for up to 2 years after native tissue reconstructive surgery with ULS or SSLF and MUS for stage 2-4 pelvic organ prolapse. On average, immediate postoperative pain is low and improves to below baseline levels by 4-6 weeks.
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